BNF:

10.1.3

Status:

Do Not Prescribe (DNP), Red

Decision Date:

May 2013

Comments

RED:

• NICE TA373 for treating juvenile idiopathic arthritis (JIA). NHSE commissioned. (Decision date - January 2016)
• NICE TA375*: for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. (Replaces TA280) (Decision date - February 2016)

*Local agreement for abatacept use as monotherapy for patients with severe RA and interstitial lung disease. (Decision date - February 2022)

• For severe treatment-resistant morphoea (localised scleroderma) (adults and children 2 years and over). NHSE commissioned (Decision date - September 2021)
• Abatacept for refractory idiopathic inflammatory myopathies (adults and children aged 2 and over). NHSE commissioned. (Decision date - February 2022
  
  

DO NOT PRESCRIBE (DNP)

• NICE TA568: for treating psoriatic arthritis after DMARDS. (Terminated appraisal) (Decision date -April 2019)
  
• NICE TA715: Adalimumab, etanercept and infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed. (Decision date - August 2021)

Do Not Prescribe (DNP) Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again